CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ANI Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ANI Pharmaceuticals Inc
210 Main Street West
Phone: (218) 634-3500p:218 634-3500 BAUDETTE, MN  56623  United States Ticker: ANIPANIP
Business Summary
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
6794 Patent owners and lessors

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Patrick D.Walsh 63 9/8/2020 5/17/2018
President, Chief Executive Officer, Director Nikhil S.Lalwani 46 9/8/2020 9/8/2020
Chief Financial Officer, Senior Vice President Stephen P.Carey 53 8/1/2022 5/6/2016
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Cell Genesys, Inc. 500 Forbes Boulevard, South San Francisco CA United States
Alimera Sciences Europe Limited 77 Sir John Rogerson's Quay Dublin 2 Ireland
Alimera Sciences Inc STE 290, 6120 WINDWARD PARKWAY ALPHARETTA GA United States
ANI Pharmaceuticals, Inc. 210 Main Street West Baudette MN United States
Novitium Pharma LLC 70 Lake Dr East Windsor NJ United States

Business Names
Business Name
Alimera Sciences B.V.
Alimera Sciences Europe Limited
Alimera Sciences Inc
12 additional Business Names available in full report.

General Information
Number of Employees: 897 (As of 12/31/2024)
Outstanding Shares: 21,773,510 (As of 2/21/2025)
Shareholders: 358
Stock Exchange: NASD
Federal Tax Id: 582301143
Fax Number: (218) 634-3540


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 12, 2025